Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W9ZY
|
|||
Former ID |
DIB009367
|
|||
Drug Name |
CE-326597
|
|||
Synonyms |
CE-326597; UNII-1FGZ6L9SF2; 1FGZ6L9SF2; CHEMBL1269258; CE 326597; CE-326,597; GTPL9055; BDBM50329179; DB12694; compound 4a [PMID: 20851601]; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (-)-; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (S)-; J3.552.307C
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Discontinued in Phase 2 | [1] | |
Company |
Pfizer Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C37H34N6O2
|
|||
Canonical SMILES |
CC(C)N(CC1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N4C(=NN=C4C5=CC=CC=C5)C(C2=O)CC6=CNC7=CC=CC=C76
|
|||
InChI |
1S/C37H34N6O2/c1-25(2)41(23-26-13-5-3-6-14-26)34(44)24-42-32-19-11-12-20-33(32)43-35(27-15-7-4-8-16-27)39-40-36(43)30(37(42)45)21-28-22-38-31-18-10-9-17-29(28)31/h3-20,22,25,30,38H,21,23-24H2,1-2H3/t30-/m0/s1
|
|||
InChIKey |
UBNMGTSDHSQBEL-PMERELPUSA-N
|
|||
CAS Number |
CAS 870615-40-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cholecystokinin receptor type A (CCKAR) | Target Info | Agonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Pancreatic secretion | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00542009) A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight. U.S. National Institutes of Health. | |||
REF 2 | Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.